About Protogenin
Protogenin (PRTG) is a protein
from Homo sapiens identified by UniProt accession
Q2VWP7, 1150 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | Protogenin |
|---|
| UniProt accession | Q2VWP7 |
|---|
| Gene | PRTG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1150 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (77)
Diseases linked to this target (Open Targets).
- cortical surface area measurement · score 0.45
- brain measurement · score 0.42
- cortical thickness · score 0.42
- neuroimaging measurement · score 0.41
- neurodegenerative disease · score 0.34
- self reported educational attainment · score 0.34
- testicular carcinoma · score 0.29
- risk-taking behaviour · score 0.29
- Testicular Germ Cell Tumor · score 0.29
- mean corpuscular volume · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2VWP7-F1 | alphafold | PREDICTED | 73.77 | — |
Amino-acid sequence (1150 residues)
MAPPLRPLAR LRPPGMLLRA LLLLLLLSPL PGVWCFSELS FVKEPQDVTV TRKDPVVLDC QAHGEVPIKV TWLKNGAKMS ENKRIEVLSN GSLYISEVEG RRGEQSDEGF YQCLAMNKYG AILSQKAHLA LSTISAFEVQ PISTEVHEGG VARFACKISS HPPAVITWEF NRTTLPMTMD RITALPTGVL QIYDVSQRDS GNYRCIAATV AHRRKSMEAS LTVIPAKESK SFHTPTIIAG PQNITTSLHQ TVVLECMATG NPKPIISWSR LDHKSIDVFN TRVLGNGNLM ISDVRLQHAG VYVCRATTPG TRNFTVAMAT LTVLAPPSFV EWPESLTRPR AGTARFVCQA EGIPSPKMSW LKNGRKIHSN GRIKMYNSKL VINQIIPEDD AIYQCMAENS QGSILSRARL TVVMSEDRPS APYNVHAETM SSSAILLAWE RPLYNSDKVI AYSVHYMKAE GLNNEEYQVV IGNDTTHYII DDLEPASNYT FYIVAYMPMG ASQMSDHVTQ NTLEDVPLRP PEISLTSRSP TDILISWLPI PAKYRRGQVV LYRLSFRLST ENSIQVLELP GTTHEYLLEG LKPDSVYLVR ITAATRVGLG ESSVWTSHRT PKATSVKAPK SPELHLEPLN CTTISVRWQQ DVEDTAAIQG YKLYYKEEGQ QENGPIFLDT KDLLYTLSGL DPRRKYHVRL LAYNNIDDGY QADQTVSTPG CVSVRDRMVP PPPPPHHLYA KANTSSSIFL HWRRPAFTAA QIINYTIRCN PVGLQNASLV LYLQTSETHM LVQGLEPNTK YEFAVRLHVD QLSSPWSPVV YHSTLPEAPA GPPVGVKVTL IEDDTALVSW KPPDGPETVV TRYTILYASR KAWIAGEWQV LHREGAITMA LLENLVAGNV YIVKISASNE VGEGPFSNSV ELAVLPKETS ESNQRPKRLD SADAKVYSGY YHLDQKSMTG IAVGVGIALT CILICVLILI YRSKARKSSA SKTAQNGTQQ LPRTSASLAS GNEVGKNLEG AVGNEESLMP MIMPNSFIDA KGGTDLIINS YGPIIKNNSK KKWFFFQDSK KIQVEQPQRR FTPAVCFYQP GTTVLISDED SPSSPGQTTS FSRPFGVAAD TEHSANSEGS HETGDSGRFS HESNDEIHLS SVISTTPPNL
Explore Protogenin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets